AUTL Stock Overview
A clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Autolus Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.95 |
| 52 Week High | US$6.63 |
| 52 Week Low | US$1.87 |
| Beta | 2.02 |
| 1 Month Change | -14.85% |
| 3 Month Change | -33.67% |
| 1 Year Change | -68.09% |
| 3 Year Change | -50.13% |
| 5 Year Change | -76.16% |
| Change since IPO | -92.20% |
Recent News & Updates
Autolus Therapeutics Will Remain Depressed For A While
Feb 05Is Autolus Therapeutics (NASDAQ:AUTL) A Risky Investment?
Jan 07
AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
Nov 21Recent updates
Autolus Therapeutics Will Remain Depressed For A While
Feb 05Is Autolus Therapeutics (NASDAQ:AUTL) A Risky Investment?
Jan 07AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
Nov 21Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Sep 06Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?
Aug 15Autolus Therapeutics: Major Inflection Point On The Horizon
Jul 31Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
May 14We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely
Nov 06Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
Jun 26We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth
Mar 09Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?
Dec 12Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy
Oct 12Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching
Aug 17Autolus Therapeutics Q2 2022 Earnings Preview
Aug 03Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
Apr 19Shareholder Returns
| AUTL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.4% | 2.2% | -2.2% |
| 1Y | -68.1% | -1.9% | 18.3% |
Return vs Industry: AUTL underperformed the US Biotechs industry which returned -1.4% over the past year.
Return vs Market: AUTL underperformed the US Market which returned 20.8% over the past year.
Price Volatility
| AUTL volatility | |
|---|---|
| AUTL Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 17.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AUTL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AUTL's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 467 | Chris Itin | www.autolus.com |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma.
Autolus Therapeutics plc Fundamentals Summary
| AUTL fundamental statistics | |
|---|---|
| Market cap | US$518.94m |
| Earnings (TTM) | -US$270.23m |
| Revenue (TTM) | US$10.09m |
51.4x
P/S Ratio-1.9x
P/E RatioIs AUTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AUTL income statement (TTM) | |
|---|---|
| Revenue | US$10.09m |
| Cost of Revenue | US$128.22m |
| Gross Profit | -US$118.12m |
| Other Expenses | US$152.10m |
| Earnings | -US$270.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | -1,170.59% |
| Net Profit Margin | -2,677.90% |
| Debt/Equity Ratio | 52.2% |
How did AUTL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 04:05 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Autolus Therapeutics plc is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ingrid Gafanhão | Bryan Garnier & Co |
| Rajan Sharma | Goldman Sachs |
| Biren Amin | Jefferies LLC |